David Russler-Germain, MD/PhD

This account is verified. Learn more

@dgermain21

Assistant Professor, lymphoma physician-scientist
@WashUOncology @SitemanCenter
All views 100% my own.

St. Louis, MO Joined January 2009

846 Following 3.9K Followers 51K Posts

Latest posts 5

Pinned post

David Russler-Germain, MD/PhD @dgermain21 Jul 3, 2023

Pretty much everyone who knows me knows I'm a big fan of bispecific antibodies for B-NHL. For a summary of key landmarks in this space, emerging evidence and lessons from recent clinical trials, and exciting new directions, check out our review:

frontiersin.org/journals/oncol…

www.frontiersin.org Frontiers | T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and... Several key advances in the treatment of B-cell non-Hodgkin lymphoma (B-NHL) over the past two decades have strategically exploited B-cell lineage markers su...

David Russler-Germain, MD/PhD @dgermain21 4d

I’m sorry to be such a pest but seriously? Let’s do our science and patients justice by getting this right. These curves and the numbers just don’t make sense. And some trainee seeing this is going to put this in a talk they give and confuse the heck out of people.

David Russler-Germain, MD/PhD @dgermain21 4d

This is a really interesting commentary. I assumed it was going to be about somatic mutation patterns (which aren’t ready for prime time in cHL) but actually addresses the risk/benefit balance with ICI toxicity specifically. I feel this is extra relevant to early-stage cHL, with fantastic outcomes already without ICI. I may sound like a broken record to some close friends, but what will NNT vs NNH be in this setting?

Mostafa Faisal @MostafaFaisal14 5d

💡The Cure–Toxicity Dilemma: Personalizing Frontline Immunotherapy in Hodgkin Lymphoma @BloodPortfolio @KFSHRC by @riadelfakih ✌️👌💪
ashpublications.org/bloodict/artic…

View quoted post on X

David Russler-Germain, MD/PhD @dgermain21 5d

Yes, with a few big caveats.

(1) You’re not included here if transformation is biopsy-proven, and we know that correlates with higher SUVs. So in transformation-ruled-out cases of FL, then maybe baseline SUV isn’t prognostic.

(2) Choice of regimen may also be influenced by factors such as SUV (and LDH, etc) such that patients may be shunted towards RCHOP the higher the SUVs.

But an important study either way!

Uriel Suárez Verified account @UsuarezMD 5d

“These findings demonstrate that baseline SUVmax provides no incremental prognostic information beyond established clinical indices in HTB FL treated with contemporary
immunochemotherapy and maintenance therapy.”
View quoted post on X

David Russler-Germain, MD/PhD @dgermain21 5d

I’m bullish on AI, and I am pro-dissemination/ infographics, but I have issues with generative AI “data”. Take a look at these K-M curves. Even putting the unnecessary and misleading cropped axes aside, the curves are just…wrong. They do not reflect the landmark outcomes/numbers written next to them. I’d encourage everyone to take extra care when making and interpreting these types of presentations.

Benlazar S M A @smbenlazar 5d

#ASH26 #HL #lymsm Individual patient data comparison of BrECADD and nivolumab-AVD in advanced-stage classic Hodgkin lymphoma: A joint GHSG/SWOG analysis of HD21 and S1826
onlineprogram.hematology.org/paper-details.…

View quoted post on X